Opendata, web and dolomites

Super-Vaccine SIGNED

Exploring the potential applications of live viral vaccine encoded small-hairpin-RNAs in improving both vaccine safety and efficacy through RNA-interference and stimulation of the innate immune system

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Super-Vaccine project word cloud

Explore the words cloud of the Super-Vaccine project. It provides you a very rough idea of what is the project "Super-Vaccine" about.

feasible    stimulation    hairpin    inducers    recombine    explore    potent    virus    strategic    strains    programs    healthcare    live    harmony    interference    exclusively    expression    wild    viral    shrnas    designed    food    desirable    security    efforts    followed    perspective    propagation    efficacy    ifn    appropriately    outline    market    attenuated    explored    strategy    launched    vaccine    inhibit    modifying    reduce    instrumental    priorities    wt    vaccination    replication    mind    potency    ultimately    viruses    spread    rnas    immune    trials    2016    progression    recombination    primary    lower    genetically    cyprinid    express    circulating    rnai    vitro    doses    innate    herpesvirus    small    vaccines    disease    societal    manufacturing    ongoing    global    rna    safety    functioning    economically    interventions    roadmap    meet    strain    intrinsic    reducing    beneficial    vivo    levels    basis    occurrences    innovation    tomorrow    interferon    capacity   

Project "Super-Vaccine" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE DE LIEGE 

Organization address
address: PLACE DU 20 AOUT 7
city: LIEGE
postcode: 4000
website: www.ulg.ac.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-CAR
 Starting year 2018
 Duration (year-month-day) from 2018-09-19   to  2020-09-18

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE LIEGE BE (LIEGE) coordinator 160˙800.00

Map

 Project objective

Live vaccines represent one of the most important and effective interventions against the spread of viral disease. As such, they are instrumental in addressing ongoing societal challenges in areas such as healthcare and global food security. However, their capacity to genetically recombine with wild type (WT) viruses circulating in the field remains a primary safety concern. Modifying live vaccine strains to reduce such occurrences would be highly desirable from a safety perspective. Also efforts to enhance the intrinsic potency of vaccine strains would be very beneficial. This would facilitate the use of much lower doses, while reducing the manufacturing resources required to meet market needs and the cost of vaccination programs.

With this in mind, this project will explore a novel strategy to improve both the safety and efficacy of live viral vaccine strains by modifying them to express small-hairpin-RNAs (shRNAs), which can be designed to:

i) Exclusively inhibit WT virus replication/propagation via RNA-interference (RNAi), thus reducing the levels of WT available for recombination with vaccine strains during vaccination i.e. improving safety

ii) Increase live vaccine strain stimulation of the innate immune system by functioning as potent inducers of Type-1 Interferon (IFN-I) expression during vaccination i.e. enhancing efficacy

This novel strategy will be explored by modifying an existing attenuated Cyprinid herpesvirus-3 vaccine strain to express appropriately designed shRNAs, followed by an assessment of their impact on both WT virus replication and IFN-I expression in-vitro, providing a basis for future progression to in-vivo trials.

Ultimately, if feasible, this novel vaccine design strategy may be applied in the control of many economically important viruses. Also elements of this project are in harmony with the “Strategic European Roadmap for the Vaccines of Tomorrow” launched in 2016 to outline specific EU priorities in future vaccine innovation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUPER-VACCINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUPER-VACCINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

ActinSensor (2019)

Identification and characterization of a novel damage sensor for cytoskeletal proteins in Drosophila

Read More  

INSPiRE (2018)

The Influence of Information Search on Preference Formation and Choice

Read More